Corbus Pharmaceuticals Holdings, Inc. (CRBP) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Corbus Pharmaceuticals reported revenue of $0. Net income was -$78.5M, or -$5.90 per diluted share. Operating activities generated -$64.5M of cash, leaving -$64.5M of free cash flow. At fiscal year end, Corbus Pharmaceuticals held $168.2M in total assets against $20.7M in total liabilities, including $28.5M of cash and equivalents.
Open the full interactive Corbus Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Corbus Pharmaceuticals Key Stats
| Share Price | $4.78 |
|---|---|
| Market Cap | $92.8M |
| 52-Week Range | $4.78 – $19.36 |
| Shares Outstanding | 19.4 million (basic, 2026 Q2) |
Corbus Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $3.9M | $881,705 | $0 | $0 | $0 | $0 |
| Operating Income | -$122.8M | -$56.0M | -$39.8M | -$45.1M | -$48.7M | -$85.3M |
| Pre-Tax Income | -$111.3M | -$45.6M | -$42.3M | -$44.6M | -$40.2M | -$78.5M |
| Income Tax | — | — | — | — | — | $0 |
| Net Income | -$111.3M | -$45.6M | -$42.3M | -$44.6M | -$40.2M | -$78.5M |
| Diluted EPS | -$42.60 | -$11.10 | -$10.15 | -$10.31 | -$3.68 | -$5.90 |
Corbus Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$23.3M | -$20.6M | -$23.0M | -$35.0M |
| Diluted EPS | -$1.90 | -$1.54 | -$1.23 | -$1.81 |
Corbus Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $85.4M | $25.0M | $17.0M | $13.7M | $17.2M | $28.5M |
| Current Assets | $92.1M | $100.2M | $60.2M | $23.5M | $153.0M | $167.0M |
| Total Assets | $102.3M | $107.7M | $66.3M | $28.3M | $155.9M | $168.2M |
| Current Liabilities | $31.9M | $17.0M | $12.6M | $31.9M | $11.8M | $20.7M |
| Total Long-Term Debt | $21.2M | $18.7M | $18.8M | $17.9M | — | — |
| Total Liabilities | $57.0M | $38.6M | $33.3M | $35.2M | $13.5M | $20.7M |
| Shareholders' Equity | $45.3M | $69.1M | $33.0M | -$6.9M | $142.4M | $147.5M |
Corbus Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$99.7M | -$48.2M | -$37.5M | -$36.1M | -$41.8M | -$64.5M |
| Cash From Investing | -$484,491 | -$73.4M | $30.1M | $35.6M | -$121.3M | -$1.6M |
| Cash From Financing | $154.9M | $60.8M | -$533,615 | -$2.8M | $166.6M | $77.4M |
| Free Cash Flow | -$100.2M | -$48.2M | -$37.6M | -$36.1M | — | -$64.5M |
Figures from Corbus Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Corbus Pharmaceuticals financials page for every line item.
Corbus Pharmaceuticals Company Profile
| Ticker | CRBP |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Norwood, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001595097 |
Frequently Asked Questions
What was Corbus Pharmaceuticals' revenue in fiscal 2025?
Corbus Pharmaceuticals (CRBP) reported revenue of $0 for fiscal 2025.
What is Corbus Pharmaceuticals' annual revenue history?
Corbus Pharmaceuticals' annual revenue by fiscal year: 2020: $3.9M; 2021: $881,705; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Corbus Pharmaceuticals' net income in fiscal 2025?
Corbus Pharmaceuticals reported net income of -$78.5M for fiscal 2025.
What was Corbus Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Corbus Pharmaceuticals' diluted EPS was -$5.90 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Corbus Pharmaceuticals generate in fiscal 2025?
Corbus Pharmaceuticals generated -$64.5M of free cash flow in fiscal 2025.
What was Corbus Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Corbus Pharmaceuticals reported revenue of $0.
How many shares of Corbus Pharmaceuticals are outstanding?
Corbus Pharmaceuticals reported a weighted average of 19.4 million basic shares outstanding in 2026 Q2.
What is Corbus Pharmaceuticals' market cap?
Based on its latest closing price, Corbus Pharmaceuticals (CRBP) has a market capitalization of about $92.8M.
When does Corbus Pharmaceuticals' fiscal year end?
Corbus Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Corbus Pharmaceuticals headquartered?
Corbus Pharmaceuticals lists its business address in Norwood, Massachusetts in its SEC filings.